Aditxt (NASDAQ:ADTX – Get Free Report) and Sol-Gel Technologies (NASDAQ:SLGL – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.
Risk & Volatility
Aditxt has a beta of 1.37, meaning that its stock price is 37% more volatile than the S&P 500. Comparatively, Sol-Gel Technologies has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500.
Insider and Institutional Ownership
15.5% of Aditxt shares are owned by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are owned by institutional investors. 0.0% of Aditxt shares are owned by company insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Aditxt and Sol-Gel Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aditxt | -360,152.50% | -374.60% | -105.93% |
| Sol-Gel Technologies | -910.14% | -44.05% | -36.96% |
Analyst Recommendations
This is a summary of recent recommendations for Aditxt and Sol-Gel Technologies, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aditxt | 1 | 0 | 0 | 0 | 1.00 |
| Sol-Gel Technologies | 1 | 0 | 4 | 2 | 3.00 |
Sol-Gel Technologies has a consensus price target of $197.50, indicating a potential upside of 251.11%. Given Sol-Gel Technologies’ stronger consensus rating and higher probable upside, analysts clearly believe Sol-Gel Technologies is more favorable than Aditxt.
Valuation and Earnings
This table compares Aditxt and Sol-Gel Technologies”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aditxt | $14,336.00 | 0.02 | -$41.71 million | ($100,788.35) | -0.00 |
| Sol-Gel Technologies | $19.39 million | 9.49 | -$6.13 million | ($5.64) | -9.97 |
Sol-Gel Technologies has higher revenue and earnings than Aditxt. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.
Summary
Sol-Gel Technologies beats Aditxt on 13 of the 15 factors compared between the two stocks.
About Aditxt
Aditxt, Inc. (NASDAQ: ADTX) is a biotechnology company focused on developing technologies designed to monitor and improve the human immune system. Its work centers on immune profiling, precision health and personalized medicine, with the goal of helping healthcare providers and researchers better understand individual immune responses. The company’s primary technology platform, AditxtScore, is designed to analyze multiple immune system biomarkers simultaneously. The platform is intended for applications including disease detection, monitoring immune responses to infections and vaccines, and supporting the development of personalized treatment strategies.
About Sol-Gel Technologies
Sol-Gel Technologies is an Israel-based dermatology company that develops topical treatments for skin conditions. Its proprietary technology uses silica-based microencapsulation to formulate active ingredients for topical use. The company’s products include Epsolay, a benzoyl peroxide cream approved in the United States for inflammatory lesions of rosacea, and Twyneo, a topical combination of tretinoin and benzoyl peroxide approved for acne vulgaris. Sol-Gel has pursued commercialization and licensing opportunities in the United States and other markets.
Receive News & Ratings for Aditxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aditxt and related companies with MarketBeat.com's FREE daily email newsletter.
